SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Alex Lukianov, Chairman and Chief Executive Officer, and Kevin O'Boyle, Executive Vice President and Chief Financial Officer, are scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference at the Grand Hyatt New York Hotel on Tuesday, September 9, 2008, at 8:35 a.m. ET.
A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.
NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.
The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
which, if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those expressed or
implied by such forward-looking statements. The potential risks and
uncertainties that could cause actual growth and results to differ
materially include, but are not limited to: the uncertain process of
seeking regulatory approval or clearance for NuVasive's products or
devices, including risks that such process could be significantly delayed;
the possibility that the FDA may require significant changes to NuVasive's
products or clinical studies; the risk that products may not perform as
intended and may therefore not achieve commercial success; the risk that
competitors may develop superior products or may have a greater market
position enabling more successful commercialization; the risk that
additional clinical data may call into question the benefits of NuVasive's
products to patients, hospitals and surgeons; and other risks and
uncertainties more fully described in NuVasive's press releases and
periodic filings with the Securities and Exchange Commission. NuVasive's
public filings with the Securities and Exchange Commission are available at
http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking
statement to reflect events or circumstances arising after the date on
which it was made.
Kevin C. O'Boyle
EVP & Chief Financial Officer
Nick Laudico/Zack Kubow
The Ruth Group
The Ruth Group
|SOURCE NuVasive, Inc.|
Copyright©2008 PR Newswire.
All rights reserved